Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712251 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
A NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis, sponsored by Venova Medical.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT06712251: Active NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis, sponsored by Venova Medical.
NCT06712251 is a NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis that is active but no longer recruiting, run by Venova Medical. The registered enrollment target is 20 participants, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06712251, a NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis, is active but no longer recruiting, sponsored by Venova Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
Primary Outcome
The proportion of participants that reach the binary outcome of Physiologic Maturation (mature/unmature). Physiologic Maturation is a composite measure, reached when Duplex ultrasound demonstrates a brachial artery blood flow of ≥ 500 ml/min and an outflow vein diameter of ≥ 5 mm.
Conditions Studied
Interventions
- DEVICE Velocity pAVF System
Study Locations (5)
Texas
- Texas Research Institute - Fort Worth
- STAR Vascular - San Antonio
Alabama
- Trinity Research Group - Dothan
California
- Apex Research - Riverside
Florida
- American Access Care of Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2027-01-04 |
| Phase | NA |
What the registry record for NCT06712251 still lists
NCT06712251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 1 intervention - of which Velocity pAVF System is the first listed.
NCT06712251 lists 5 locations in 4 states (Texas, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT06712251 about?
NCT06712251 is a clinical study titled "Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access". The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
What is the current status of trial NCT06712251?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-01-08. Estimated completion is 2027-01-04.
What conditions does trial NCT06712251 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease Requiring Hemodialysis.
What interventions are being tested in trial NCT06712251?
The interventions under investigation include: Velocity pAVF System (DEVICE).
Who is sponsoring clinical trial NCT06712251?
This trial is sponsored by Venova Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712251 being conducted?
This trial has 5 study locations across Alabama, California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06712251's enrollment target sits among peer trials
20 10th of 10 higher than 1 of 10 other End Stage Renal Disease (ESRD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease (ESRD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
COMPLETED · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI